320 related articles for article (PubMed ID: 31839169)
1. Adjuvant endocrine therapy for premenopausal women: risk stratification, type and duration.
Francis PA
Breast; 2019 Nov; 48 Suppl 1():S85-S88. PubMed ID: 31839169
[TBL] [Abstract][Full Text] [Related]
2. Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT.
Pagani O; Francis PA; Fleming GF; Walley BA; Viale G; Colleoni M; Láng I; Gómez HL; Tondini C; Pinotti G; Di Leo A; Coates AS; Goldhirsch A; Gelber RD; Regan MM;
J Clin Oncol; 2020 Apr; 38(12):1293-1303. PubMed ID: 31618131
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials.
Regan MM; Pagani O; Fleming GF; Walley BA; Price KN; Rabaglio M; Maibach R; Ruepp B; Coates AS; Goldhirsch A; Colleoni M; Gelber RD; Francis PA; ;
Breast; 2013 Dec; 22(6):1094-100. PubMed ID: 24095609
[TBL] [Abstract][Full Text] [Related]
4. Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials.
Bernhard J; Luo W; Ribi K; Colleoni M; Burstein HJ; Tondini C; Pinotti G; Spazzapan S; Ruhstaller T; Puglisi F; Pavesi L; Parmar V; Regan MM; Pagani O; Fleming GF; Francis PA; Price KN; Coates AS; Gelber RD; Goldhirsch A; Walley BA
Lancet Oncol; 2015 Jul; 16(7):848-58. PubMed ID: 26092816
[TBL] [Abstract][Full Text] [Related]
5. Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer.
Bui KT; Willson ML; Goel S; Beith J; Goodwin A
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD013538. PubMed ID: 32141074
[TBL] [Abstract][Full Text] [Related]
6. Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials.
Saha P; Regan MM; Pagani O; Francis PA; Walley BA; Ribi K; Bernhard J; Luo W; Gómez HL; Burstein HJ; Parmar V; Torres R; Stewart J; Bellet M; Perelló A; Dane F; Moreira A; Vorobiof D; Nottage M; Price KN; Coates AS; Goldhirsch A; Gelber RD; Colleoni M; Fleming GF; ; ;
J Clin Oncol; 2017 Sep; 35(27):3113-3122. PubMed ID: 28654365
[TBL] [Abstract][Full Text] [Related]
7. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
Francis PA; Pagani O; Fleming GF; Walley BA; Colleoni M; Láng I; Gómez HL; Tondini C; Ciruelos E; Burstein HJ; Bonnefoi HR; Bellet M; Martino S; Geyer CE; Goetz MP; Stearns V; Pinotti G; Puglisi F; Spazzapan S; Climent MA; Pavesi L; Ruhstaller T; Davidson NE; Coleman R; Debled M; Buchholz S; Ingle JN; Winer EP; Maibach R; Rabaglio-Poretti M; Ruepp B; Di Leo A; Coates AS; Gelber RD; Goldhirsch A; Regan MM;
N Engl J Med; 2018 Jul; 379(2):122-137. PubMed ID: 29863451
[TBL] [Abstract][Full Text] [Related]
8. Navigating the Challenges of Endocrine Treatments in Premenopausal Women with ER-Positive Early Breast Cancer.
Colleoni M; Munzone E
Drugs; 2015 Aug; 75(12):1311-21. PubMed ID: 26177891
[TBL] [Abstract][Full Text] [Related]
9. Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials.
Regan MM; Francis PA; Pagani O; Fleming GF; Walley BA; Viale G; Colleoni M; Láng I; Gómez HL; Tondini C; Pinotti G; Price KN; Coates AS; Goldhirsch A; Gelber RD
J Clin Oncol; 2016 Jul; 34(19):2221-31. PubMed ID: 27044936
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT.
Francis PA; Fleming GF; Láng I; Ciruelos EM; Bonnefoi HR; Bellet M; Bernardo A; Climent MA; Martino S; Bermejo B; Burstein HJ; Davidson NE; Geyer CE; Walley BA; Ingle JN; Coleman RE; Müller B; Le Du F; Loibl S; Winer EP; Ruepp B; Loi S; Colleoni M; Coates AS; Gelber RD; Goldhirsch A; Regan MM;
J Clin Oncol; 2023 Mar; 41(7):1370-1375. PubMed ID: 36493334
[No Abstract] [Full Text] [Related]
11. Adjuvant endocrine therapy for premenopausal women: Type and duration.
Francis PA
Breast; 2017 Aug; 34 Suppl 1():S108-S111. PubMed ID: 28669713
[TBL] [Abstract][Full Text] [Related]
12. Impact on disease-free survival of the duration of ovarian function suppression, as postoperative adjuvant therapy, in premenopausal women with hormone receptor-positive breast cancer: a retrospective single-institution study.
Ozaki Y; Tanabe Y; Tamura N; Ogura T; Kondoh C; Miura Y; Yoshimura K; Kawabata H; Takano T
Breast Cancer; 2018 May; 25(3):343-349. PubMed ID: 29357022
[TBL] [Abstract][Full Text] [Related]
13. Revisiting adjuvant ovarian suppression in premenopausal breast cancer patients.
Abbas W; Rao RR
Indian J Cancer; 2019; 56(4):293-296. PubMed ID: 31607695
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant ovarian suppression in premenopausal breast cancer.
Francis PA; Regan MM; Fleming GF; Láng I; Ciruelos E; Bellet M; Bonnefoi HR; Climent MA; Da Prada GA; Burstein HJ; Martino S; Davidson NE; Geyer CE; Walley BA; Coleman R; Kerbrat P; Buchholz S; Ingle JN; Winer EP; Rabaglio-Poretti M; Maibach R; Ruepp B; Giobbie-Hurder A; Price KN; Colleoni M; Viale G; Coates AS; Goldhirsch A; Gelber RD; ;
N Engl J Med; 2015 Jan; 372(5):436-46. PubMed ID: 25495490
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant endocrine therapy for premenopausal women with hormone-responsive breast cancer.
Mathew A; Davidson NE
Breast; 2015 Nov; 24 Suppl 2():S120-5. PubMed ID: 26255743
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials.
Pagani O; Walley BA; Fleming GF; Colleoni M; Láng I; Gomez HL; Tondini C; Burstein HJ; Goetz MP; Ciruelos EM; Stearns V; Bonnefoi HR; Martino S; Geyer CE; Chini C; Puglisi F; Spazzapan S; Ruhstaller T; Winer EP; Ruepp B; Loi S; Coates AS; Gelber RD; Goldhirsch A; Regan MM; Francis PA;
J Clin Oncol; 2023 Mar; 41(7):1376-1382. PubMed ID: 36521078
[No Abstract] [Full Text] [Related]
17. [Factors related to adjuvant ovarian function suppression in premenopausal breast cancer patients].
Liang Y; Chen XS; Wu JY; Huang O; Zong Y; Nie LJ; Fang Q; He JR; Zhu L; Chen WG; Li YF; Shen KW
Zhonghua Zhong Liu Za Zhi; 2016 May; 38(5):357-62. PubMed ID: 27188608
[TBL] [Abstract][Full Text] [Related]
18. Luteininzing hormone releasing hormones analogs in combination with tamoxifen for the adjuvant treatment of premenopausal women with hormone receptor positive breast cancer.
Conte B; Poggio F; Del Mastro L
Expert Opin Pharmacother; 2017 Sep; 18(13):1357-1362. PubMed ID: 28764603
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.
Pagani O; Regan MM; Walley BA; Fleming GF; Colleoni M; Láng I; Gomez HL; Tondini C; Burstein HJ; Perez EA; Ciruelos E; Stearns V; Bonnefoi HR; Martino S; Geyer CE; Pinotti G; Puglisi F; Crivellari D; Ruhstaller T; Winer EP; Rabaglio-Poretti M; Maibach R; Ruepp B; Giobbie-Hurder A; Price KN; Bernhard J; Luo W; Ribi K; Viale G; Coates AS; Gelber RD; Goldhirsch A; Francis PA; ;
N Engl J Med; 2014 Jul; 371(2):107-18. PubMed ID: 24881463
[TBL] [Abstract][Full Text] [Related]
20. Challenges in Treating Premenopausal Women with Endocrine-Sensitive Breast Cancer.
Azim HA; Davidson NE; Ruddy KJ
Am Soc Clin Oncol Educ Book; 2016; 35():23-32. PubMed ID: 27249683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]